CA2666581A1 - Composition de pulverisation sans pressurisation contenant de la buprenorphine pour administration par voie transmuqueuse - Google Patents

Composition de pulverisation sans pressurisation contenant de la buprenorphine pour administration par voie transmuqueuse Download PDF

Info

Publication number: CA2666581A1
Authority: CA; Canada
Prior art keywords: composition; composition according; buprenorphine; ethanol; solvent
Prior art date: 2006-10-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002666581A

Other languages

English (en)

Inventor

Clive Booles

Padriac O'brien

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmasol Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-18

Filing date

2007-10-17

Publication date

2008-04-24

2007-10-17 Application filed by Individual filed Critical Individual

2008-04-24 Publication of CA2666581A1 publication Critical patent/CA2666581A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 190
229960001736 buprenorphine Drugs 0.000 title claims abstract description 78
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title claims abstract description 74
239000007921 spray Substances 0.000 title claims abstract description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 141
239000002904 solvent Substances 0.000 claims abstract description 45
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 16
239000006193 liquid solution Substances 0.000 claims abstract description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
229940081974 saccharin Drugs 0.000 claims description 26
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 26
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 24
235000019204 saccharin Nutrition 0.000 claims description 22
239000001525 mentha piperita l. herb oil Substances 0.000 claims description 21
238000009472 formulation Methods 0.000 claims description 20
235000019477 peppermint oil Nutrition 0.000 claims description 17
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 16
229940041616 menthol Drugs 0.000 claims description 16
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 10
229940085605 saccharin sodium Drugs 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
229940127240 opiate Drugs 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 7
239000003963 antioxidant agent Substances 0.000 claims description 6
239000000796 flavoring agent Substances 0.000 claims description 6
239000011521 glass Substances 0.000 claims description 6
239000004615 ingredient Substances 0.000 claims description 6
235000006708 antioxidants Nutrition 0.000 claims description 5
239000002738 chelating agent Substances 0.000 claims description 5
230000003078 antioxidant effect Effects 0.000 claims description 4
235000013355 food flavoring agent Nutrition 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
238000004891 communication Methods 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 2
239000000243 solution Substances 0.000 description 34
NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 32
238000003860 storage Methods 0.000 description 16
UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 10
229960001889 buprenorphine hydrochloride Drugs 0.000 description 9
239000003380 propellant Substances 0.000 description 8
239000007788 liquid Substances 0.000 description 7
210000004877 mucosa Anatomy 0.000 description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
229960004873 levomenthol Drugs 0.000 description 6
201000009032 substance abuse Diseases 0.000 description 6
230000000202 analgesic effect Effects 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
239000003826 tablet Substances 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
230000008901 benefit Effects 0.000 description 4
235000003599 food sweetener Nutrition 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
-1 nonoxinols Substances 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
229940037001 sodium edetate Drugs 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
239000003765 sweetening agent Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
208000026251 Opioid-Related disease Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000463 material Substances 0.000 description 3
201000005040 opiate dependence Diseases 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
239000006190 sub-lingual tablet Substances 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
241000238366 Cephalopoda Species 0.000 description 2
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000003840 Opioid Receptors Human genes 0.000 description 2
108090000137 Opioid Receptors Proteins 0.000 description 2
229920002675 Polyoxyl Polymers 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
239000004141 Sodium laurylsulphate Substances 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000000337 buffer salt Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000004040 coloring Methods 0.000 description 2
229960002069 diamorphine Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
229960002428 fentanyl Drugs 0.000 description 2
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
239000004031 partial agonist Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000003495 polar organic solvent Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000015424 sodium Nutrition 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000004296 sodium metabisulphite Substances 0.000 description 2
235000010262 sodium metabisulphite Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
235000018185 Betula X alpestris Nutrition 0.000 description 1
235000018212 Betula X uliginosa Nutrition 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
241001539473 Euphoria Species 0.000 description 1
206010015535 Euphoric mood Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
244000004005 Nypa fruticans Species 0.000 description 1
235000005305 Nypa fruticans Nutrition 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229960001716 benzalkonium Drugs 0.000 description 1
CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000005178 buccal mucosa Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001273 butane Substances 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940061631 citric acid acetate Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000005356 container glass Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000002788 crimping Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000004088 foaming agent Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
210000003128 head Anatomy 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
229960003943 hypromellose Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
102000048260 kappa Opioid Receptors Human genes 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000008263 liquid aerosol Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229960003951 masoprocol Drugs 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000002991 molded plastic Substances 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
102000051367 mu Opioid Receptors Human genes 0.000 description 1
229940041676 mucosal spray Drugs 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229940013712 pineapple extract Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
239000000770 propane-1,2-diol alginate Substances 0.000 description 1
229940093625 propylene glycol monostearate Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000009877 rendering Methods 0.000 description 1
239000003566 sealing material Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
FVEFRICMTUKAML-UHFFFAOYSA-M sodium tetradecyl sulfate Chemical compound [Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O FVEFRICMTUKAML-UHFFFAOYSA-M 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
229940095172 subutex Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
150000003445 sucroses Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229920001169 thermoplastic Polymers 0.000 description 1
239000004416 thermosoftening plastic Substances 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
229920001664 tyloxapol Polymers 0.000 description 1
229960004224 tyloxapol Drugs 0.000 description 1
238000013022 venting Methods 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
108020001588 κ-opioid receptors Proteins 0.000 description 1
108020001612 μ-opioid receptors Proteins 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002666581A 2006-10-18 2007-10-17 Composition de pulverisation sans pressurisation contenant de la buprenorphine pour administration par voie transmuqueuse Abandoned CA2666581A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0620661.9A GB0620661D0 (en)	2006-10-18	2006-10-18	Novel compounds
GB0620661.9		2006-10-18
PCT/GB2007/050639 WO2008047163A1 (fr)	2006-10-18	2007-10-17	Composition de pulvérisation sans pressurisation contenant de la buprénorphine pour administration par voie transmuqueuse

Publications (1)

Publication Number	Publication Date
CA2666581A1 true CA2666581A1 (fr)	2008-04-24

Family

ID=37507923

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002666581A Abandoned CA2666581A1 (fr)	2006-10-18	2007-10-17	Composition de pulverisation sans pressurisation contenant de la buprenorphine pour administration par voie transmuqueuse

Country Status (8)

Country	Link
EP (1)	EP2081574A1 (fr)
CN (1)	CN101573116A (fr)
AU (1)	AU2007311621A1 (fr)
CA (1)	CA2666581A1 (fr)
GB (2)	GB0620661D0 (fr)
IL (1)	IL197908A0 (fr)
WO (1)	WO2008047163A1 (fr)
ZA (1)	ZA200902123B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8852638B2 (en)	2005-09-30	2014-10-07	Durect Corporation	Sustained release small molecule drug formulation
KR101230804B1 (ko)	2006-07-21	2013-02-08	바이오딜리버리 사이언시스 인터내셔널 인코포레이티드	향상된 흡수를 갖는 경점막 전달 장치
GB2461681A (en) *	2008-04-17	2010-01-13	Pharmasol Ltd	Buprenorphine liquid spray formulation with solvent and antioxidant
JP2010531807A (ja)	2007-05-25	2010-09-30	トルマーセラピューティクス，インコーポレイテッド	リスペリドン化合物の徐放送達製剤
WO2010072398A2 (fr) *	2008-12-22	2010-07-01	Boehringer Ingelheim Limited	Formulations vétérinaires
GB2481017B (en)	2010-06-08	2015-01-07	Rb Pharmaceuticals Ltd	Microparticle buprenorphine suspension
US9272044B2 (en)	2010-06-08	2016-03-01	Indivior Uk Limited	Injectable flowable composition buprenorphine
GB2483579A (en) *	2010-06-30	2012-03-14	Londonpharma Ltd	Sublingual formulations comprising methadone and ethanol for use in reducing pain
US9901539B2 (en)	2011-12-21	2018-02-27	Biodelivery Sciences International, Inc.	Transmucosal drug delivery devices for use in chronic pain relief
WO2013096811A2 (fr) *	2011-12-21	2013-06-27	Biodelivery Sciences International, Inc.	Dispositifs d'administration transmucosale de médicament pour une utilisation dans le soulagement de la douleur chronique
GB201404139D0 (en)	2014-03-10	2014-04-23	Rb Pharmaceuticals Ltd	Sustained release buprenorphine solution formulations
JP2018531964A (ja)	2015-10-27	2018-11-01	インシス・ディベロップメント・カンパニー・インコーポレイテッド	液体ブプレノルフィン製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1296649A2 (fr) *	2000-06-22	2003-04-02	Pharmasol Limited	Compositions pharmaceutiques comprenant un analgesique opioide
CA2446904A1 (fr) *	2001-05-24	2003-04-03	Alexza Molecular Delivery Corporation	Administration d'esters medicamenteux par inhalation
WO2004071491A1 (fr) *	2003-02-04	2004-08-26	Chrysalis Technologies Incorporated	Formulations d'aerosols et distribution par aerosols de buspirone, buprenorphine, triazolam, cyclobenzaprine et zolpidem
CA2564083C (fr) *	2004-04-23	2014-02-04	Philip Morris Usa Inc.	Generateurs d'aerosol et procede de production d'aerosols

2006
- 2006-10-18 GB GBGB0620661.9A patent/GB0620661D0/en not_active Ceased
2007
- 2007-10-17 CN CNA2007800387417A patent/CN101573116A/zh active Pending
- 2007-10-17 CA CA002666581A patent/CA2666581A1/fr not_active Abandoned
- 2007-10-17 AU AU2007311621A patent/AU2007311621A1/en not_active Abandoned
- 2007-10-17 WO PCT/GB2007/050639 patent/WO2008047163A1/fr not_active Ceased
- 2007-10-17 EP EP07824851A patent/EP2081574A1/fr not_active Withdrawn
2009
- 2009-03-25 GB GB0905120A patent/GB2456434A/en not_active Withdrawn
- 2009-03-26 ZA ZA200902123A patent/ZA200902123B/xx unknown
- 2009-04-05 IL IL197908A patent/IL197908A0/en unknown

Also Published As

Publication number	Publication date
GB0620661D0 (en)	2006-11-29
AU2007311621A1 (en)	2008-04-24
IL197908A0 (en)	2009-12-24
CN101573116A (zh)	2009-11-04
GB0905120D0 (en)	2009-05-06
ZA200902123B (en)	2010-04-28
WO2008047163A1 (fr)	2008-04-24
GB2456434A (en)	2009-07-22
EP2081574A1 (fr)	2009-07-29

Publication	Publication Date	Title
CA2666581A1 (fr)	2008-04-24	Composition de pulverisation sans pressurisation contenant de la buprenorphine pour administration par voie transmuqueuse
US20090270438A1 (en)	2009-10-29	Novel compositions and formulations
US6632842B2 (en)	2003-10-14	Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
CA2673049C (fr)	2016-02-23	Preparations antinauseeuses a pulveriser, a usage oral, stables, et methodes associees
US20070212307A1 (en)	2007-09-13	Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
RS58377B1 (sr)	2019-04-30	Kompozicije koje sadrže azelastin i metode njihove upotrebe
WO2009127878A1 (fr)	2009-10-22	Solution de spray liquide renfermant de la buprénorphine, de l’éthanol et un antioxydant
WO2003037159A2 (fr)	2003-05-08	Solution d'inhalation a base d'albuterol et d'ipratropium, et systeme, kit et methode permettant de soulager les symptomes de la bronchopneumopathie chronique obstructive
JP2009544715A (ja)	2009-12-17	抗片頭痛の口腔噴霧製剤及び方法
US20060062812A1 (en)	2006-03-23	Novel compositions
US20240216360A1 (en)	2024-07-04	Drug products for intranasal administration and uses thereof
IE920484A1 (en)	1992-08-26	Pharmaceutical Formulations
US20210330903A1 (en)	2021-10-28	Multiple Dose Nasal Spray of Naloxone
US20030203930A1 (en)	2003-10-30	Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2009500387A (ja)	2009-01-08	精油を含有するフェンタニル製剤
AU2004218876B2 (en)	2007-08-02	Novel compositions containing fentanyl
ES2596359T3 (es)	2017-01-09	Formas de dosificación farmacéuticas de tizanidina y su vía de administración
CN1784228B (zh)	2012-06-06	新组合物
KR20130142990A (ko)	2013-12-30	오피오이드의 설하 전달용 약제 조성물
US8084461B2 (en)	2011-12-27	Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
AU2020340617A1 (en)	2022-03-31	Pharmaceutical composition

Legal Events

Date	Code	Title	Description
2011-10-17	FZDE	Discontinued